Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles.

ABSTRACT:

Motivation

Somatic homozygous deletions of chromosomal regions in cancer, while not necessarily oncogenic, may lead to therapeutic vulnerabilities specific to cancer cells compared with normal cells. A recently reported example is the loss of one of the two isoenzymes in glioblastoma cancer cells such that the use of a specific inhibitor selectively inhibited growth of the cancer cells, which had become fully dependent on the second isoenzyme. We have now made use of the unprecedented conjunction of large-scale cancer genomics profiling of tumor samples in The Cancer Genome Atlas (TCGA) and of tumor-derived cell lines in the Cancer Cell Line Encyclopedia, as well as the availability of integrated pathway information systems, such as Pathway Commons, to systematically search for a c

SUBMITTER: Aksoy BA 

PROVIDER: S-EPMC4080742 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature